Wegovy by Novo Nordisk - maintenance pens reshaping obesity care

Wegovy 1.7 mg maintenance pens line up in a clinic fridge, their white and green bodies catching the cold light as a nurse checks expiry dates with gloved fingers. Wegovy is Novo Nordisk’s high-dose semaglutide injection for chronic weight management in adults with obesity.

Where Wegovy 1.7 mg sits in therapy

Wegovy is based on the GLP-1 receptor agonist semaglutide and is approved in the United States and the European Union for chronic weight management in adults with obesity or overweight plus weight-related comorbidities. Patients do not start directly on 1.7 mg: Wegovy follows a fixed titration scheme from 0.25 mg up to 2.4 mg once weekly. The 1.7 mg pen serves as a key maintenance or intermediate dose for patients who cannot tolerate a rapid uptitration to the maximum 2.4 mg.

Endocrinologist Robert Kushner at Northwestern University, a leading investigator in the STEP clinical trial program, has repeatedly described Wegovy as a long-term, chronic therapy rather than a short-term “diet shot”, emphasising the need for sustainable dosing regimens. The existence of multiple Wegovy strengths, including 1.7 mg, allows physicians like Kushner to tailor the dose according to gastrointestinal tolerability and real-world adherence.

A closer look at the 1.7 mg pen

On Novo Nordisk’s US product page, Wegovy 1.7 mg is listed among five weekly single-use strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. Each pre-filled pen contains semaglutide in solution and delivers a fixed subcutaneous dose in the abdomen, thigh or upper arm. For the 1.7 mg strength, each carton typically contains four single-use pens, corresponding to four weeks of therapy when injected once weekly on the same day each week. The pens must be stored refrigerated at 2–8 °C before first use, then can be kept at room temperature up to 30 °C for a limited time depending on local labeling.

The Wegovy device shares much of its tactile design heritage with Novo Nordisk’s diabetes injection pens. The user twists off the cap, presses the pen firmly against the skin, and listens for a soft click that signals the injection has started. In the STEP 1 trial, semaglutide 2.4 mg achieved mean weight loss of around 15% of baseline body weight after 68 weeks in adults with obesity. While 1.7 mg is not the headline dose in most efficacy graphs, titration and intermediate dosing were critical in reaching that target safely.

Label, access and pricing

In the US, Wegovy received its initial FDA approval for chronic weight management in adults with BMI ?30 kg/m² or ?27 kg/m² plus at least one weight-related condition in June 2021. The approved label explicitly describes a dose escalation schedule over 16 weeks, with weekly doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. Novo Nordisk positions 1.7 mg as the pen for week 13 to week 16 of treatment, serving as the final step before patients reach the full 2.4 mg dose. For some individuals, physicians may retain 1.7 mg longer when higher doses trigger nausea or vomiting, using it as a maintenance level.

List prices for Wegovy in the US are high and usually quoted at the package level rather than per pen. According to data compiled by industry analysts and payers, a carton of Wegovy pens across strengths carries a wholesale acquisition cost just above 1,300 US dollars per month of therapy. Real out-of-pocket costs vary widely because many private insurers impose strict BMI criteria and prior authorization processes. In Germany, Wegovy was approved in early 2024, but reimbursement is limited and pricing follows local AMNOG assessment and negotiations with statutory health insurers. Availability has been constrained as Novo Nordisk prioritises existing patients and gradually increases supply.

Production, shortages and CEO stance

Novo Nordisk CEO Lars Fruergaard Jørgensen has acknowledged the strain that Wegovy’s global demand puts on the company’s manufacturing network. He has repeatedly said in earnings calls that capacity expansions in Denmark and the US are underway to support GLP-1 production, including both Ozempic and Wegovy. Still, the company has faced temporary supply interruptions for some Wegovy strengths, especially introductory doses, as regulators and physicians urge prioritisation of patients already on therapy.

On the ground, that means pharmacists sometimes tell new patients to come back in two weeks, their hands resting on empty shelf space where Wegovy cartons should be. The company has indicated that it expects a gradual normalisation of supply as new lines ramp up, but it continues to warn about potential bottlenecks in countries where launches are recent. To manage demand ethically, Jørgensen and his team have coordinated with regulators to delay some national launches, focusing quantities on markets like the US and Germany where obesity treatment infrastructure is in place.

Clinical evidence behind the pens

The STEP clinical trial programme underpins Wegovy’s approval. In STEP 1, 1,961 adults with obesity or overweight plus comorbidity were randomised to semaglutide 2.4 mg or placebo, both with lifestyle intervention. After 68 weeks, participants receiving semaglutide achieved a mean body weight reduction of 14.9%, versus 2.4% for placebo. Secondary endpoints showed improvements in cardiometabolic risk factors, including HbA1c and blood pressure. Dose escalation to 2.4 mg used the full sequence of pens, including the 1.7 mg strength, and once patients reached 2.4 mg they generally continued at that level for maintenance.

Other STEP trials extended these findings to individuals with type 2 diabetes and different BMI ranges. The trials documented predictable gastrointestinal side effects such as nausea, diarrhoea and vomiting that often peaked during dose escalation. That safety profile is one reason why the Wegovy titration steps, including the 1.7 mg week-13-to-16 phase, matter so much in routine care: they allow the body to adapt and give physicians a clear structure to pause or slow escalation. Clinical experts increasingly treat dose flexibility as a tool to maintain adherence and avoid abrupt discontinuation when side effects hit.

Target group and everyday use

Wegovy 1.7 mg pens are aimed at adults living with obesity or overweight plus weight-related health issues who have already moved through lower doses without intolerable side effects. Typical candidates are people with BMI above 30 kg/m² who have failed to achieve sufficient weight loss with diet and exercise alone. Many are in their 40s or 50s, juggling work, family and joint pain, and now face weekly injections and the discipline of sustained lifestyle change. Some clinics build structured programs around the Wegovy titration schedule, aligning diet coaching and exercise plans with the dosing calendar.

From a user’s perspective, the 1.7 mg phase often feels like the moment when the treatment becomes routine. Patients have practised injections for weeks and know the feeling of a tiny sting in the skin and the cooling sensation of alcohol swabs. If nausea flares, doctors may ask them to stay on 1.7 mg for longer instead of pushing immediately to 2.4 mg. That option gives patients psychological breathing room: they see weight loss on the scale, but the weekly dose remains manageable. Novo Nordisk’s patient materials repeatedly stress that Wegovy is meant to be combined with reduced-calorie diets and increased physical activity, not used as a stand-alone fix.

How Wegovy feeds into Novo Nordisk results

Wegovy belongs to Novo Nordisk’s obesity care segment, which has become one of the fastest-growing revenue pillars for the Danish drug maker. In recent quarterly reports, the company has highlighted double-digit growth in obesity treatments driven mainly by Wegovy in the US and Europe. Investors parse unit shipment data and capacity expansion updates closely, aware that any prolonged supply constraint can ripple through sales expectations. Novo Nordisk A/S stock is listed on Nasdaq Copenhagen, and the ISIN DK0060534915 tracks the share for European and international investors. The Wegovy franchise, including intermediate strengths like 1.7 mg, is a significant contributor to that valuation narrative.